PatientsVille.com

What is the primary objective of this study?

If we compare eradication rate of Helicobacter pylori divided to 4 groups: amoxicillin, rabeprazole, clarithromycin(AOC), amoxicillin, rabeprazole, metronidazole(AOM), treated with amoxicillin, rabeprazole for 5 day, followed by clarithromycin, metronidazole, rabeprazole for 5 days(sequential), amoxicillin, clarithromycin, metronidazole, rabeprazole(concomitant), then the eradication rate of concomitant group will be the highest.

Who is eligible to participate?

Inclusion Criteria: - patients infected with Helicobacter pylori Exclusion Criteria: - cancer - pregnancy - formerly treated with eradication

Which medical condition, disease, disorder, syndrome, illness, or injury is researched?

Gastritis, Gastric Ulcer, and Duodenal Ulcer

Study Interventions

Interventions can include giving participants drugs, medical devices, procedures, vaccines, and other products that are either investigational or already available or noninvasive approaches such as surveys, education, and interviews.

Drug:amoxicillin, clarithromycin, metronidazole, rabeprazole

Study Arms

Research studies and clinical trials typically have two or more research arms. An arm is a group of people who receive the same treatment in the study.

AOC groupAOC group: treated with amoxicillin, rabeprazole, clarithromycin for 7 days

AOM groupAOM group: treated with amoxicillin, rabeprazole, metronidazole for 7 days

Sequential groupSequential group: treated with amoxicillin, rabeprazole for 5 day, followed by clarithromycin, metronidazole, rabeprazole for 5 days

concomitant groupconcomitant group: treated with amoxicillin, clarithromycin, metronidazole, rabeprazole for 7 days

Study Status

Unknown status

Start Date: August 2013

Completed Date: February 2014

Phase: Phase 4

Type: Interventional

Design:

Primary Outcome: Evaluation of the efficacy of concomitant therapy for eradication of Helicobacter pylori

Secondary Outcome:

Study sponsors, principal investigator, and references

Principal Investigator:

Lead Sponsor: The Catholic University of Korea

Collaborator: Bucheon St. Mary's Hospital

More information:https://clinicaltrials.gov/show/NCT01922765